Safety and efficacy of pralsetinib in patients with advanced RET fusion-positive non-small cell lung cancer: Update from the ARROW trial.
Year: 2021
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Giuseppe Curigliano, Justin F. Gainor, Frank Griesinger, Michael Thomas, Vivek Subbiah, Christina S Baik, Daniel Shao-Weng Tan, Dae Ho Lee, Daniel Misch, Elena Garralda, Dong-Wan Kim, Luis G. Paz-Ares, Julien Mazieres, Stephen V. Liu, Gregory Peter Kalemkerian, Yariv Houvras, Daniel W. Bowles, Aaron Scott Mansfield, Alena Zalutskaya, Anthonie J. van der Wekken
Institutions: University of Milan, European Institute of Oncology, Massachusetts General Hospital, Carl von Ossietzky Universität Oldenburg, Pius Hospital Oldenburg, Heidelberg University, German Center for Lung Research, The University of Texas MD Anderson Cancer Center, University of Washington, National Cancer Centre Singapore, Asan Medical Center, University of Ulsan, Helios Klinikum Emil von Behring, Vall d'Hebron Hospital Universitari, Vall d'Hebron Institute of Oncology, Seoul National University Hospital, Hospital Universitario 12 De Octubre, Institut universitaire du cancer de Toulouse Oncopole, Georgetown University, University of Michigan, Weill Cornell Medicine, University of Colorado Anschutz, Mayo Clinic, Blueprint Medicines (United States), University Medical Center Groningen, University of Groningen
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W3169277288